PHILIPPE ARMAND

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology BOSTON, MA NPI 1689648263

General Payments — all program years on this page

$113,874.69

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 87
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $13,583.13 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $5,860.005
Regeneron Pharmaceuticals, Inc. $2,620.002
Genentech USA, Inc. $2,280.001
E.R. Squibb & Sons, L.L.C. $2,076.001
Acerta Pharma LLC $395.233
TAIHO ONCOLOGY, INC. $224.643
ABBVIE INC. $127.261

By program year

Program yearAmountRecords
2018 $16,097.259
2019 $28,445.5619
2020 $13,155.0010
2021 $22,322.4211
2022 $9,898.5811
2023 $10,372.7511
2024 $13,583.1316

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1101642228 E.R. Squibb & Sons, L.L.C. $2,076.00 01/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1103239429 ABBVIE INC. $127.26 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105529168 AstraZeneca Pharmaceuticals LP $290.70 09/30/2024 Compensation for serving as faculty or as a speaker for a medical education program Undisputed 01/23/2026 View at CMS
1105567054 AstraZeneca Pharmaceuticals LP $28.66 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105582920 AstraZeneca Pharmaceuticals LP $75.87 10/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1114396116 Regeneron Pharmaceuticals, Inc. $1,310.00 01/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1114396118 Regeneron Pharmaceuticals, Inc. $1,310.00 01/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1133089003 Genentech USA, Inc. $2,280.00 11/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137934593 TAIHO ONCOLOGY, INC. $163.04 09/30/2024 Compensation for serving as faculty or as a speaker for a medical education program Undisputed 01/23/2026 View at CMS
1137935289 TAIHO ONCOLOGY, INC. $45.52 10/31/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1137936821 TAIHO ONCOLOGY, INC. $16.08 09/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141589100 Merck Sharp & Dohme LLC $2,745.00 02/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141634357 Merck Sharp & Dohme LLC $65.00 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141666912 Merck Sharp & Dohme LLC $1,220.00 01/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141666914 Merck Sharp & Dohme LLC $610.00 06/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141831781 Merck Sharp & Dohme LLC $1,220.00 09/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.